每经记者｜陈星 每经编辑｜文多 9月3日早，药明合联（02268.HK，股价67.00港元，市值807.00亿港元）披露，公司将按每股58.85港元 的价格配售最多2228万股股份，预计最高所得款项总额约为13.11亿港元。配售价较最后交易日（9月2 日）收盘价（61.3港元/股）折让约4.00%，但较前五个交易日平均收盘价（57.21港元/股）溢价约 2.87%。以上款项中90%拟用于扩大公司的服务能力及产能。 同日，药明合联披露，此次配售已获控股股东药明生物（02269.HK）认购2413.40万股，对应金额约为 14.20亿港元。 记者注意到，药明合联9月2日的收盘价已较今年首个交易日收盘价翻倍，61.3港元/股的价格处于其历 史股价高位。资深投资者分析称，此刻认购药明合联的增发股份，意味着他们看好药明合联的长期成长 性和生物偶联药物CRDMO（近年来生物医药行业新兴的商业模式）赛道的潜力。 有资深投资者对《每日经济新闻》记者表示，通常，上市公司增发（配售）新股时，为了吸引投资者认 购，往往会给予一定的价格折让，以补偿投资者因持股占比摊薄而面临的短期风险。在此过程中，折让 是惯例，溢价则非常规。 "可能 ...

公告称，收益增加主要是由于全球抗体偶联药物(ADC)及更广泛生物偶联药物市场的持续活跃发展，推 动了客户数量及项目数量的增加;集团作为领先的ADC CRDMO服务提供商的稳固地位，带动其市场份 额提升;及集团项目向后期阶段的稳步推进(通常会产生更高的合约价值)。 公司凭借卓越的表现于2023年及2024年连续荣获World ADC的"最佳CDMO"奖。集团凭借持续发展荣膺 诸多奖项及成就，凸显了公司在为ADC及更广泛的生物偶联药物提供由技术创新驱动并结合强大的化 学、制造与管制(CMC)专业知识的综合服务方面处于全球领先地位。为确保集团已就持续扩大其市场份 额做好准备，并抓住全球对生物偶联药物CRDMO服务日益增长的需求，其于整个报告期内继续提升其 生产能力并吸引人才。XDP3制剂车间实现GMP放行、集团无锡基地扩建(包括在建中的XDP5制剂车间) 及新加坡新基地建设均按计划稳步推进，竣工后将带来更多单克隆抗体、DS及DP生产线、实验室及办 公室空间。 药明合联(02268)发布截至2025年6月30日止6个月的中期业绩，该集团取得收益人民币27亿元(单位下 同)，同比增加62.19%;公司拥有人应占纯利7. ...

Core Insights - WuXi AppTec (02268) reported a revenue of RMB 2.7 billion for the six months ending June 30, 2025, representing a year-on-year increase of 62.19% [1] - The net profit attributable to the company's owners was RMB 746 million, up 52.74% year-on-year, with basic earnings per share of RMB 0.62 [1] - The revenue growth was driven by the active development of the global antibody-drug conjugates (ADC) and broader bioconjugates market, leading to an increase in both client and project numbers [1] Group Performance - The CRDMO business exhibited strong momentum in the first half of 2025, with a continuous positive expansion and increased global demand for its services [2] - As of June 30, 2025, the company has empowered a total of 563 global clients through its comprehensive CRDMO capabilities and "one-stop" facilities from drug discovery to commercialization [2] - The company has successfully secured 11 PPQ (Process Performance Qualification) projects and one commercial stage project [2] Industry Recognition - The company was awarded the "Best CDMO" title by World ADC for 2023 and 2024, highlighting its excellence in providing technology-driven comprehensive services for ADCs and broader bioconjugates [2] - The company continues to enhance its production capacity and attract talent to prepare for expanding its market share and meet the growing global demand for bioconjugate CRDMO services [2] - Ongoing projects include the GMP release of the XDP3 formulation workshop, expansion of the Wuxi base, and the construction of a new facility in Singapore, which will increase production lines and laboratory space upon completion [2]